HLS Therapeutics Management
Management criteria checks 1/4
HLS Therapeutics' CEO is Craig Millian, appointed in May 2023, has a tenure of less than a year. directly owns 0.031% of the company’s shares, worth CA$47.50K. The average tenure of the management team and the board of directors is 3.4 years and 2.1 years respectively.
Key information
Craig Millian
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.03% |
| Management average tenure | 3.4yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22HLS Therapeutics (TSE:HLS) Will Pay A Dividend Of CA$0.05
Nov 29HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Aug 10Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 30CEO
Craig Millian (55 yo)
less than a year
Tenure
Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice President of Scientific Affairs | 9.8yrs | US$319.52k | 0.16% $ 236.1k | |
| Senior VP of Legal | 5.9yrs | US$431.01k | 0.0016% $ 2.4k | |
| CEO & Director | less than a year | no data | 0.031% $ 47.5k | |
| Interim CFO & Non-Independent Director | less than a year | no data | 0.013% $ 19.0k | |
| Senior Vice President of Commercial | less than a year | no data | 0.0038% $ 5.7k | |
| VP & Corporate Controller | 6.3yrs | no data | no data |
3.4yrs
Average Tenure
55yo
Average Age
Experienced Management: HLS's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.031% $ 47.5k | |
| Interim CFO & Non-Independent Director | less than a year | no data | 0.013% $ 19.0k | |
| Independent Director | 5.1yrs | US$207.50k | no data | |
| Independent Chairman of the Board | 2.8yrs | US$210.00k | 0.30% $ 460.8k | |
| Independent Director | 6.1yrs | US$218.69k | no data | |
| Independent Director | 2.8yrs | US$206.43k | 0.0016% $ 2.4k | |
| Independent Director | 1.4yrs | US$18.05k | 0.0055% $ 8.4k | |
| Independent Director | less than a year | no data | no data |
2.1yrs
Average Tenure
55yo
Average Age
Experienced Board: HLS's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.